Nine acute myelogenous leukemia(AML) patients with a translocation 8;21, who were treated at Keio University Hospital between 1983 and August 1990, were reviewed. All of them were classified into AML-M2 subtype of the French-American-British classification. It formed 43% of all M2 cases. The patients' mean age was 47 years. Neutrophil alkaline phosphatase score was lower than normal and complete remision(CR) was achieved in all cases. In statistical analysis, patients with the t(8;21) showed a longer CR duration and a higher percentage of eosinophils than the other AML-M2 patients without this karyotype (p<0.05, p<0.01, respectively). As an additional chromosomal abberation, two patients showed a loss of Y chromosome at first diagnosis and another patient did a deletion of 12p at the 3rd relapse and an elongation of 20q in addition to the 12p at the 4th relapse. Although patients with the t(8;21) are regarded as a favorable group in respect of survival, we found a subset of patients who had poor 
Introduction
Since Rowley1 first described the t(8;21) in AML, numerous reports have been presented unique charac teristics with this cytogenetic abnormality. The picture described has included the following features: generally young adult onset, male predominance, milder clinical course with high remission rates and relatively long survival, marrow cytology conforming to the M2 group of French-American-British (FAB) classification with granulocytic maturation and occasionally eosinophilia, low neutrophil alkaline phosphatase (NAP) score and predisposition to solid tumor formation. However, few patients present all these features.
Here we carried out this study to know whether each patient presents these features or not and found clinical heterogeneity in AML patients with the t(8;21).
Patients and Method
We investigated 62 AML patients who were treated at Keio University Hospital between 1983 and August 1990. All patients were classified according to FAB classifi cation. For the primary remission induction treatment, patients received chemotherapy with a combination of daunorubicin (DNR), behenoyl cytosine arabinoside (BHAC), 6-mercaptopurine (6-MP) and prednisolone (PSL) (BHAC-DMP). In cases of having complications, such as diabetes mellitus or gastric ulcers, PSL was excluded from the regimen. Following it, they received the alternative intensification therapy: BHAC-DMP and VEMP (vincristine, endoxane, 6-MP and PSL). Complete remission (CR) was diagnosed upon the attainment of 80 points on the Kimura's remission criteria together with the absence of blasts in the peripheral blood (PB Differences between the characteristics in M2 cases with the t(8;21) and those without the t(8;21) were analysed using the Wilcoxon-Mann-Whitney U test.
Results
Of those 62 AML patients reviewed, 22 were classified into AML-M2 of FAB and all 9 patients with the t(8;21) were included in this group. The clinical characteristics of the 9 patients with the t(8;21) were detailed in Table  1 . There were 7 males and 2 females with an age range of 25-69 years old (mean 47). Eight of 9 patients achieved a CR with first induction therapy. Another patient (Case 6) needed 2 courses of induction therapy to attain a CR. Case 1 alone is alive now 6 years after diagnosis, main taining the first CR. The other patients relapsed within 3 years (from 6 to 32 months) after achieving CR and some of them re-entered to CR. But finally most have died due to the exacerbation of the diseases. Case 4 and 6 had there 1st relapse, each with bilateral pleural infiltrations and mediastinal tumors. Case 8 had there 3rd relapse with a paravertebral tumor. The remission rate was 100%. The mean CR duration and survival were 19 months (range 5 to 72 months) and 28 months (range 6 to 73 months), respectively. A significantly longer CR duration was observed for the t(8;21) group compared with the other M2 group without the t(8;21) (p<0.05) (19 months vs 6 months). Survival did not significantly differ. Of the pretreatment parameters, higher percentage of eosinophils was observed (p<0.01) (4.6% vs 0.4%) ( Table 3) .
Discussion
In recent years, uniform classification system for leukemia, such as the FAB criteria, have allowed cor relations between subtypes of AML and specific chro mosomal abnormalities. It has been reported that t(8;21) is frequently seen in AML-M2 subtype. In this study, they formed 15% of AML and 43% of M2, confirming the frequency reported previously. 5-12 Although most reports have stated that t(8;21) occurs exclusively in AML-M2,3 a few reports are found which state that Ml or M4 subtype can be seen with a significant frequency. For example, by Davey and associates,4 3 of 10 patients were classified into AML-M1. In our study, all of 9 patients were classified into AML-M2.
Although this karyotype has been reported to occur in younger age groups (around 30 years old)5-7 and that fact may be one of reasons for its association with good prognosis, we found only one patient (Case 2) under 40 years old and the mean age was even higher than the group without the t(8;21).
Although high CR ratio of 75% to 95% are reported,-11 remission duration and overall survival are not always good and various among the reports. In the Fourth International Workshop on Chromosome in Leukemia which collected data on 45 patients of the t(8;21), median survival was 9.5 months.12 Swirsky reported on 30 patients with 24 months of it and stated that their prognosis might be worse than that in other patients of comparable age of AML.8 Median survial with 18 months in our study is comparable to these reports. Although the mean CR duration was longer than the group without the t(8;21), most of them finally relapsed and died of the disease.
Of interest is that 2 of 9 patients (22%) developed solid tumors with leukemic infiltrations. This rate is comparable to that in the series by Swirsky (21%)8 or by Abe (17%). 13 Swirsky stated that predisposition to solid tumor formation might be unique to the t(8;21) cases. In both our patients, it concurred with marrow relapses. Interestingly, one of them (Case 8) was accompanied with additional chromosorpal aberration, 12p-and 20q+, at the time of tumor formation. As remission duration was short after the treatment of tumor formation in both cases, it might be a poor prognostic sign in this group. In common with previous reports, there is a high incidence of sex chromosome loss (50%-85%) 5, 8, 12, 14, 15 Berger et al 14 stated that patients who lost a sex chromo some had a shorter median survival than those with the t(8;21) alone. In our study, only 2 of 9 (22%) showed a loss of sex chromosome and one of them (Case 4) had an aggressive course complicating pleural infiltrations and died at 15 months.
NAP score is almost always low in this disease. 16 it reflects that malignant cells originate from stem cell level and much of granulocytes are involved just like as chronic myelogenous leukemia. As we expected, all patients showed lower than normal NAP score. However, their NAP score were not different significantly from those in other M2 cases, suggesting sharing mechanism might be involved in M2 cases regardless of karyotype.
According to Swirsky, marked BM eosinophilia (5% or more) was present in 12 of 33 cases with the t(8;21).8 In our study, 3 patients who showed more than 5% of eosinophils in BM followed better clinical courses includ ing long survival. Now we have been working on bone marrow eosinophilia as a prognostic indicator (manu script in preparation). It must be emphasized that cases with lower percentage of eosinophils showed more aggressive clinical courses including 3 patients ac companied with extra marrow legion. Although patients with the t(8;21) have been regarded as a favorable prog nostic group, it appeared heterogenous in terms of prog nosis as well as in other characteristics. By knowing characteristics associated with poor prognosis in t(8;21) cases as well as other acute leukemia, we could select those who need intensive or more investigational approaches in treatment.
